mesalamine has been researched along with (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrzejak, V; Barczyk, A; Body-Malapel, M; Chavatte, P; Desreumaux, P; Djouina, M; El Bakali, J; Furman, C; Gilleron, P; Klupsch, F; Lambert, DM; Lipka, E; Mansouri, R; Millet, R; Muccioli, GG | 1 |
1 other study(ies) available for mesalamine and (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
| Article | Year |
|---|---|
4-Oxo-1,4-dihydropyridines as selective CB₂ cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis.
Topics: Adamantane; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Blood Proteins; CHO Cells; Colitis; Cricetinae; Cricetulus; Humans; Intestinal Absorption; Ligands; Mice; Microsomes, Liver; Protein Binding; Pyridines; Radioligand Assay; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Trinitrobenzenesulfonic Acid | 2012 |